Three UBA1 clones for a unique VEXAS syndrome
Authors:
- 12 September 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (2) , e48-e50
Abstract
Benjamin Podvin, Nathalie Cleenewerck, Olivier Nibourel, Alice Marceau-Renaut, Pauline Roynard, Claude Preudhomme, Nicolas Duployez, Louis Terriou; Three UBA1 cKeywords
This publication has 7 references indexed in Scilit:
- Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter studyBlood, 2022
- Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patientsRMD Open, 2022
- VEXAS Syndrome: A Novelty in MDS LandscapeDiagnostics, 2022
- Azacytidine Treatment for VEXAS SyndromeHemaSphere, 2021
- Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registryBritish Journal of Haematology, 2021
- Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?Seminars in Hematology, 2021
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory DiseaseNew England Journal of Medicine, 2020